CRIS Current Research Information System

DI NUNNO, VINCENZO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 2.088
AS - Asia 1.736
EU - Europa 1.147
AF - Africa 192
SA - Sud America 125
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 5.293
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.066
SG - Singapore 662
CN - Cina 481
VN - Vietnam 237
IT - Italia 187
GB - Regno Unito 185
SE - Svezia 178
HK - Hong Kong 150
DE - Germania 134
NL - Olanda 87
SC - Seychelles 86
BR - Brasile 84
RU - Federazione Russa 81
IE - Irlanda 71
KR - Corea 65
IN - India 59
CH - Svizzera 55
CI - Costa d'Avorio 46
FR - Francia 40
FI - Finlandia 37
TG - Togo 28
JP - Giappone 27
AR - Argentina 23
ZA - Sudafrica 20
BG - Bulgaria 17
ID - Indonesia 17
BE - Belgio 15
AT - Austria 13
EE - Estonia 11
JO - Giordania 10
MX - Messico 10
UA - Ucraina 10
BD - Bangladesh 9
CA - Canada 9
PL - Polonia 9
NG - Nigeria 6
EC - Ecuador 5
PY - Paraguay 5
SK - Slovacchia (Repubblica Slovacca) 5
MY - Malesia 4
UZ - Uzbekistan 4
AU - Australia 3
ES - Italia 3
LT - Lituania 3
TR - Turchia 3
VE - Venezuela 3
CO - Colombia 2
DZ - Algeria 2
NI - Nicaragua 2
PE - Perù 2
TW - Taiwan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AE - Emirati Arabi Uniti 1
BB - Barbados 1
BY - Bielorussia 1
CD - Congo 1
CZ - Repubblica Ceca 1
EG - Egitto 1
EU - Europa 1
GN - Guinea 1
HR - Croazia 1
KG - Kirghizistan 1
LB - Libano 1
LK - Sri Lanka 1
LV - Lettonia 1
MA - Marocco 1
NO - Norvegia 1
PK - Pakistan 1
RO - Romania 1
SA - Arabia Saudita 1
UY - Uruguay 1
Totale 5.293
Salva come PNG Salva come JPEG
Città #
Singapore 444
Chandler 239
Ashburn 233
Santa Clara 171
Fairfield 150
Hong Kong 146
Southend 144
Hefei 143
Beijing 81
Seattle 79
Princeton 72
Dublin 71
Houston 71
Woodbridge 67
Boardman 66
Dong Ket 65
Seoul 65
Wilmington 60
Bern 55
Cambridge 52
Ann Arbor 49
Abidjan 46
Bologna 35
Helsinki 35
Los Angeles 34
Hanoi 29
Lomé 28
Berlin 25
Ho Chi Minh City 25
Buffalo 22
Dallas 20
Redondo Beach 20
Milan 18
New York 17
Sofia 17
Westminster 15
Bengaluru 13
Brussels 13
Tokyo 13
Jakarta 12
Redwood City 12
Turin 12
Frankfurt am Main 11
Amman 10
Chicago 10
London 10
Nanjing 10
Des Moines 9
Olalla 9
Redmond 9
Falkenstein 8
Falls Church 8
San Diego 8
Yubileyny 8
Boston 7
Boydton 7
Florence 7
Naples 7
Rome 7
Shanghai 7
Tianjin 7
Glasgow 6
Phoenix 6
Shenyang 6
São Paulo 6
Warsaw 6
Bühl 5
Forlì 5
Guangzhou 5
Harbin 5
Jinan 5
Kyoto 5
Montescudo 5
Montreal 5
Padua 5
Tongling 5
Vienna 5
Wuhan 5
Zhengzhou 5
Žilina 5
Abeokuta 4
Bentivoglio 4
Brooklyn 4
Changsha 4
Changzhou 4
Denver 4
Hebei 4
Kumar 4
Ningbo 4
Nuremberg 4
Qingdao 4
San Francisco 4
Shijiazhuang 4
Torino 4
Baoding 3
Brescia 3
Buenos Aires 3
Cardiff 3
Da Nang 3
Ha Long 3
Totale 3.317
Salva come PNG Salva come JPEG
Nome #
A case of complete response to nivolumab after long-term progression-free survival with tyrosine kinase inhibitor. 207
Circulating tumor cells in genitourinary tumors 191
Clinical management of a pituitary gland metastasis from clear cell renal cell carcinoma. 169
Anti-programmed cell death-1 and anti-programmed cell death ligand-1 immune-related liver diseases: from clinical pivotal studies to real-life experience 163
Successful treatment with personalized dosage of imatinib in elderly patients with gastrointestinal stromal tumors 151
Cabozantinib-related cardiotoxicity: a prospective analysis in a "real world" cohort of metastatic renal cell carcinoma patients 151
Immune checkpoint inhibitors for metastatic bladder cancer 143
Biological issues with cabozantinib in bone metastatic renal cell carcinoma and castration-resistant prostate cancer 140
New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes. 133
Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis 123
The human microbiota and prostate cancer: Friend or foe? 123
Clinical and Molecular Features of Patients with Gliomas Harboring IDH1 Non-canonical Mutations: A Systematic Review and Meta-Analysis. 121
Glioblastoma: Emerging treatments and novel trial designs 120
A Meta-Analysis Evaluating Clinical Outcomes of Patients with Renal Cell Carcinoma Harboring Chromosome 9P Loss. 112
Immortal time bias question in the association between toxicity and outcome of immune checkpoint inhibitors 112
Association between socioeconomic status and survival in glioblastoma: An Italian single-centre prospective observational study 112
Engineered CAR-T and novel CAR-based therapies to fight the immune evasion of glioblastoma: gutta cavat lapidem 112
Adjuvant therapy in renal cell carcinoma: Is it the right strategy to inhibit VEGF? 111
The clinical and prognostic role of ALK in glioblastoma 111
The Biological and Clinical Role of the Telomerase Reverse Transcriptase Gene in Glioblastoma: A Potential Therapeutic Target? 106
Should CARMENA Really Change our Attitude Towards Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy. 104
Diagnostic and Therapeutic Strategy in Anaplastic (Malignant) Meningioma, CNS WHO Grade 3 103
Clinical efficacy of immune checkpoint inhibitors in patients with brain metastases 102
Is Molecular Tailored-Therapy Changing the Paradigm for CNS Metastases in Breast Cancer? 100
Distinct MRI pattern of "pseudoresponse" in recurrent glioblastoma multiforme treated with regorafenib: Case report and literature review 96
Recent Advances in Liquid Biopsy in Patients With Castration Resistant Prostate Cancer 94
Key role of obesity in genitourinary tumors with emphasis on urothelial and prostate cancers 92
Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study 92
Resistance to systemic agents in renal cell carcinoma predict and overcome genomic strategies adopted by tumor 91
Re: Robert J. Motzer, Alain Ravaud, Jean-Jacques Patard, et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.09.008 91
Expertise is crucial to prolong survival in average risk medulloblastoma: long-term results of a retrospective study 91
Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma 89
Idh1 non-canonical mutations and survival in patients with glioma 89
IDH1105GGT single nucleotide polymorphism improves progression free survival in patients with IDH mutated grade II and III gliomas 88
Discovering the molecular landscape of meningioma: The struggle to find new therapeutic targets 88
Optimizing renal function and outcome of patients with cT2 renal cell carcinoma 86
Rare Primary Central Nervous System Tumors in Adults: An Overview 86
Meningioma: Not always a benign tumor. A review of advances in the treatment of meningiomas 84
Systemic Treatment for Metastatic Hormone Sensitive Prostate Cancer: A Comprehensive Meta-Analysis Evaluating Efficacy and Safety in Specific Sub-Groups of Patients 80
IDH Inhibitors and Beyond: The Cornerstone of Targeted Glioma Treatment 78
Radiomics, mirnomics, and radiomirRNomics in glioblastoma: defining tumor biology from shadow to light 77
Machine learning in neuro-oncology: toward novel development fields 74
Hypothyroidism in patients with hepatocellular carcinoma receiving cabozantinib: An unassessed issue 73
Liquid Biopsy in Glioblastoma Management: From Current Research to Future Perspectives. 68
Immunotherapy in renal cell carcinoma: latest evidence and clinical implications 64
Molecular mechanisms related to hormone inhibition resistance in prostate cancer 63
Cabazitaxel in metastatic prostate cancer 57
Adjuvant therapy in renal cell carcinoma-is pharmacogenomics assessment another element to select our patients? 43
The role of the MET/AXL pathway as a new target for multikinase inhibitors in renal cell carcinoma 42
Immortal Time Bias Question in the Association Between Toxicity and Outcome of Immune Checkpoint Inhibitors 40
Targeting Mitochondria in Glioma: New Hopes for a Cure 39
Addition of Primary Metastatic Site on Bone, Brain, and Liver to IMDC Criteria in Patients With Metastatic Renal Cell Carcinoma: A Validation Study 37
Combination immunotherapy in metastatic renal cell carcinoma. Are we leaving something back? 33
Improving IMDC Prognostic Prediction Through Evaluation of Initial Site of Metastasis in Patients With Metastatic Renal Cell Carcinoma 31
Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis 24
Hypothyroidism in patients with hepatocellular carcinoma receiving cabozantinib: an unassessed issue 23
null 22
N-Myc a key gene promoting a worst prostate cancer progression 21
New Hormonal Agents in Patients With Nonmetastatic Castration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes 20
Re: Jose Luis Perez-Gracia, Yohann Loriot, Jonathan E. Rosenberg, et al. Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Outcomes by Prior Number of Regimens. Eur Urol 2018;73:462–8 18
Future perspectives for personalized immunotherapy in renal cell carcinoma 17
Pembrolizumab plus axitinib: A new treatment option for patients with metastatic renal cell carcinoma 15
Totale 5.436
Salva come PNG Salva come JPEG
Categoria #
all - tutte 19.335
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 19.335
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021227 0 0 0 0 0 4 6 6 35 14 7 155
2021/2022609 12 18 15 24 53 22 9 61 56 59 187 93
2022/2023974 90 106 42 100 64 120 28 67 181 37 52 87
2023/2024309 44 62 25 34 19 45 17 26 8 18 2 9
2024/20251.229 65 165 108 86 236 62 64 34 9 115 79 206
2025/20261.432 231 354 266 213 298 70 0 0 0 0 0 0
Totale 5.436